Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 934826-68-3
2. Skq1 Bromide
3. Skq1
4. Skq-1 Bromide
5. 934826-68-3 (bromide)
6. (10-(4,5-dimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl)triphenylphosphonium Bromide
7. Skq1 (visomitin), Ethanol Solution
8. 7b14500j3e
9. 2,3-dimethyl-5-(10-(triphenyl-l-5-phosphanyl)decyl)-1,4-benzoquinone Hydrobromide
10. Phosphonium, (10-(4,5-dimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)decyl)triphenyl-, Bromide (1:1)
11. Skq1(visomitin)
12. Visomitin (skq1)
13. Schembl12231062
14. Unii-7b14500j3e
15. Bcp15201
16. Ex-a2505
17. Mfcd29477502
18. S9729
19. Akos037515539
20. Cs-8068
21. Ac-36103
22. Hy-100474
23. D80700
24. Plastoquinonyl-decyl-triphenylphosphonium Bromide
25. A857620
26. Q27896317
27. Plastoquinonyl-decyl-triphenylphosphonium Bromide [who-dd]
28. 10-(4,5-dimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl-triphenylphosphanium;bromide
29. Skq-1;skq 1;visomitin; Pdtp; Plastoquinonyl Decyltriphenyl Phosphonium Bromide
| Molecular Weight | 617.6 g/mol |
|---|---|
| Molecular Formula | C36H42BrO2P |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 14 |
| Exact Mass | 616.21058 g/mol |
| Monoisotopic Mass | 616.21058 g/mol |
| Topological Polar Surface Area | 34.1 Ų |
| Heavy Atom Count | 40 |
| Formal Charge | 0 |
| Complexity | 804 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Drugs in Development
Details:
SkQ1 (visomitin), is a cardiolipin peroxidation inhibitor, designed to sustain and restore mitochondrial function and interrupt apoptosis in mitochondrial conditions like LHON, dry eye disease and glaucoma.
Lead Product(s): Visomitin
Therapeutic Area: Ophthalmology Brand Name: SkQ1
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 24, 2022
Lead Product(s) : Visomitin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mitotech CSO to Present at Mitochondria-Targeted Drug Development Summit
Details : SkQ1 (visomitin), is a cardiolipin peroxidation inhibitor, designed to sustain and restore mitochondrial function and interrupt apoptosis in mitochondrial conditions like LHON, dry eye disease and glaucoma.
Product Name : SkQ1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2022
Details:
USFDA has granted ODD for the company’s topical cardiolipin peroxidation inhibitor, SkQ1(Visomitin), for the treatment of Leber’s Hereditary Optic Neuropathy a rare inherited condition that can lead to blindness.
Lead Product(s): Visomitin
Therapeutic Area: Ophthalmology Brand Name: SkQ1
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 15, 2021
Lead Product(s) : Visomitin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHON
Details : USFDA has granted ODD for the company’s topical cardiolipin peroxidation inhibitor, SkQ1(Visomitin), for the treatment of Leber’s Hereditary Optic Neuropathy a rare inherited condition that can lead to blindness.
Product Name : SkQ1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 15, 2021
Details:
VISTA-2 is a multi-centre, randomized, double-blind, placebo-controlled clinical study involving two treatment arms: SkQ1 ophthalmic solution and vehicle solution, administered BID.
Lead Product(s): Visomitin
Therapeutic Area: Ophthalmology Brand Name: SkQ1
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Essex Biotechnology
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 25, 2020
Lead Product(s) : Visomitin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Essex Biotechnology
Deal Size : Inapplicable
Deal Type : Inapplicable
Mitotech and Essex Bio-Technology Complete Enrollment in VISTA-2 – a pivotal Phase 3 Clinical St...
Details : VISTA-2 is a multi-centre, randomized, double-blind, placebo-controlled clinical study involving two treatment arms: SkQ1 ophthalmic solution and vehicle solution, administered BID.
Product Name : SkQ1
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
55
PharmaCompass offers a list of Visomitin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Visomitin manufacturer or Visomitin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Visomitin manufacturer or Visomitin supplier.
PharmaCompass also assists you with knowing the Visomitin API Price utilized in the formulation of products. Visomitin API Price is not always fixed or binding as the Visomitin Price is obtained through a variety of data sources. The Visomitin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Visomitin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Visomitin, including repackagers and relabelers. The FDA regulates Visomitin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Visomitin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Visomitin supplier is an individual or a company that provides Visomitin active pharmaceutical ingredient (API) or Visomitin finished formulations upon request. The Visomitin suppliers may include Visomitin API manufacturers, exporters, distributors and traders.
Visomitin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Visomitin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Visomitin GMP manufacturer or Visomitin GMP API supplier for your needs.
A Visomitin CoA (Certificate of Analysis) is a formal document that attests to Visomitin's compliance with Visomitin specifications and serves as a tool for batch-level quality control.
Visomitin CoA mostly includes findings from lab analyses of a specific batch. For each Visomitin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Visomitin may be tested according to a variety of international standards, such as European Pharmacopoeia (Visomitin EP), Visomitin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Visomitin USP).
